PayerTalkCE Presents: Major Advances in the Management of Retinopathy of Prematurity (ROP)

Learn About:

1. The burden of retinopathy of prematurity
2. Evidence-based treatment recommendations
3. Strategies for improving eye care for children

Expert Faculty Presenters:

Jeffrey D. Dunn, PharmD, MBA Chief Clinical Officer Cooperative Benefits Group (CBG) Click here for biography Edward H. Wood, MD Ophthalmologist and Retinal Specialist Austin Retina Associates Click here for biography

Target Audience
This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
Anti-VEGF treatment has recently been shown to be effective for retinopathy of prematurity (ROP), an eye disease that can occur in some premature babies born before 31 weeks. ROP is an important cause of severe visual impairment in childhood. While managed care professionals are familiar with available biologics targeting vascular endothelial growth factor, the nuances of their use and expanding indications remain an educational need. In particular, education is lacking regarding emerging pharmacologic treatment strategies for ROP.

Educational Objectives
After completing this activity, the participant should be better able to:

• Characterize the health burden of retinopathy of prematurity
• Assess evidence-based treatment recommendations
• Identify strategies for improving eye care for children by engaging managed care stakeholders

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Medical Education Resources designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.

UAN:JA0003680-9999-23-157-L01-P
Type of Activity: Knowledge

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
Medical Education Resources designates this enduring activity for a maximum of 0.5 ANCC nursing contact hours. Nurses will be awarded contact hours upon successful completion of the activity.

DISCLOSURE OF CONFLICTS OF INTEREST
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies relevant financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation form, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.